FDA Grants Accelerated Approval for Novel Herpes Virus-Based Melanoma Therapy

The FDA has granted accelerated approval to Tudriqev, a new therapy utilizing a modified herpes virus to treat advanced melanoma. This approval provides clinicians with an additional treatment option for this aggressive cancer, potentially improving outcomes for patients facing limited therapeutic choices.